tiprankstipranks
Trending News
More News >
ImmuPharma PLC (GB:IMM)
LSE:IMM
UK Market

ImmuPharma (IMM) Income Statement

Compare
27 Followers

ImmuPharma Income Statement

Last quarter (Q2 2025), ImmuPharma's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q2, ImmuPharma's net income was £-919.44K. See ImmuPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
£ 0.00£ 0.00£ 0.00£ 118.35K£ 126.67K
Gross Profit
£ -63.88K£ -37.61K£ -118.00K£ 118.35K£ 126.67K
Operating Expenses
£ 2.67M£ 3.15M£ 2.91M£ 6.71M£ 5.72M
Depreciation and Amortization
£ 63.88K£ 37.61K£ 117.56K£ 114.12K£ 170.96K
EBITDA
£ -2.61M£ -3.02M£ -2.91M£ -8.70M£ -6.84M
Operating Income
£ -2.28M£ -3.06M£ -3.03M£ -6.59M£ -5.59M
Other Income/Expenses
£ -104.00K£ -356.00K£ -1.43M£ -2.35M£ -1.66M
Pretax Income
£ -2.78M£ -3.42M£ -4.46M£ -8.94M£ -7.25M
Net Income
£ -2.48M£ -2.92M£ -3.81M£ -8.17M£ -6.86M
Per Share Metrics
Basic EPS
£ -0.01£ -0.01£ -0.01£ -0.03£ -0.03
Diluted EPS
£ -0.01£ -0.01£ -0.01£ -0.03£ -0.03
Weighted Average Shares Outstanding
413.92M 360.71M 302.91M 251.16M 200.00M
Weighted Average Shares Outstanding (Diluted)
416.44M 362.00M 302.91M 251.16M 200.18M
Currency in GBP

ImmuPharma Earnings and Revenue History